Table 1. Anthropometric data of the study population and relevant medications in CKD patients.
Patients (36m / 20f) | Controls (28m / 32f) | |
---|---|---|
Age [y] | 12.0 (4.00–18.0) | 13.5 (7.00–18.0) |
absolute BMI [kg/m2] | 18.6 (9.25–35.9) | 19.8 (15.0–28.1) |
standardized BMI [SDS] | 0.12 (-7.47–3.14) | 0.19 (-1.32–1.92) |
eGFR [ml/min/1.73m2] | 117 (22.8–200) | |
Duration of disease [y] | 6.92 (0.17–16.7) | |
Antihypertensive Drugs (yes / no) | 36/20 | |
ACE-Inhibitors | 22 | |
AT1 receptor antagonists | 14 | |
Beta blockers | 13 | |
Alpha blockers | 3 | |
Vasodilators | 10 | |
Diuretics | 15 | |
Immunosuppressive therapy (yes / no) | 20/36 | |
Corticosteroids | 11 | |
Calcineurin-Inhibitors | 14 | |
Everolimus | 1 | |
Mycophenolate mofetil | 14 | |
Statins | 5 | |
Erythropoietin | 7 | |
Growth Hormone | 1 | |
25-Hydroxyvitamin D / Calcitriol | 25 |